Galapagos announces encouraging new results from ongoing phase 1/2 study of cd19 car t-cell therapy, glpg5101, in patients with relapsed/refractory non-hodgkin lymphoma

Mechelen, belgium; december 7, 2024, 18:30 cet; galapagos nv (euronext & nasdaq: glpg) today announced additional data from the ongoing phase 1/2 atalanta-1 study of its cd19 car t-cell therapy, glpg5101. the results, featured in an oral presentation at the 66 th american society of hematology (ash) annual meeting and exposition, demonstrate an encouraging efficacy and safety profile in patients with relapsed/refractory non-hodgkin lymphoma (r/r nhl). most patients in the study received glpg5101 as a fresh, fit, stem-like, early memory cd19 car t-cell therapy, with a median vein-to-vein time of seven days.
CAR Ratings Summary
CAR Quant Ranking